Product image of Izgrev (Hydrochlorothiazide, Irbesartan) supplied by GNH India

Izgrev

Active Ingredient:
Hydrochlorothiazide, Irbesartan
Origin:
EU

Izgrev (Hydrochlorothiazide, Irbesartan)

Hydrochlorothiazide and Irbesartan, the active ingredients in Izgrev, are a thiazide diuretic and an angiotensin II receptor blocker presented as oral tablets for systemic use. The combination is indicated for managing hypertension and associated fluid retention.

GNH India supplies Izgrev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Izgrev is manufactured under EU GMP guidelines, ensuring batch consistency and patient safety.

Manufacturer / TM Owner

Swyssi Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Izgrev combines a thiazide diuretic and an angiotensin II receptor blocker to treat conditions related to elevated blood pressure and fluid overload.
  • Hypertension: lowers systolic and diastolic pressure, helping prevent cardiovascular complications.
  • Edema: enhances urinary sodium and water excretion, reducing swelling associated with heart failure or renal disease.
  • Cardiovascular risk reduction: improves overall blood pressure control, contributing to decreased risk of stroke and myocardial infarction.

How It Works

  • Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions result in lowered systemic vascular resistance and decreased fluid overload.

Side Effects

Common Side Effects

  • Dizziness or light‑headedness, especially after the first dose.
  • Increased frequency of urination.
  • Mild headache.
  • Electrolyte disturbances such as low potassium.
  • Fatigue or weakness.
  • Transient rise in blood urea nitrogen.

Serious or Rare Side Effects

  • Severe dehydration or electrolyte imbalance.
  • Angioedema or swelling of the face, lips, or throat.
  • Acute kidney injury or significant rise in serum creatinine.
  • Hyperkalemia, particularly when combined with potassium‑sparing agents.
  • Allergic skin reactions, including rash or Stevens‑Johnson syndrome.

Precautions & Warnings

Before initiating therapy, patients should be evaluated for renal function, electrolyte status, and blood pressure stability.

  • Monitor electrolytes: regular checks of sodium, potassium, and magnesium are advised.
  • Assess renal function: evaluate serum creatinine and eGFR periodically.
  • Use caution in hepatic impairment: dose adjustments may be required.
  • Avoid in severe hypotension: the drug can exacerbate low blood pressure.
  • Pregnancy safety unknown: discuss risks with a healthcare professional.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Izgrev may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid)

  • Lithium: increased lithium levels may cause toxicity.
  • ACE inhibitors or other ARBs: combined use can lead to severe hyperkalemia and renal impairment.
  • Potassium‑sparing diuretics: risk of dangerous potassium elevation.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may reduce antihypertensive effect and impair renal function.
  • Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.

Frequently Asked Questions

Izgrev is prescribed for patients who need control of high blood pressure (hypertension) and for those with fluid retention (edema) related to heart failure, kidney disease, or other causes of excess extracellular fluid.

Irbesartan blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urine output and lowering plasma volume. Together they lower blood pressure and reduce swelling.

The specific dose of Izgrev is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Dosage information is provided on the prescription label.

The safety of Izgrev in pregnancy and lactation has not been established. Healthcare providers should weigh potential benefits against possible risks and discuss alternative treatment options with pregnant or nursing patients.

To request Izgrev, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Izgrev combines a thiazide diuretic with an angiotensin II receptor blocker, offering dual mechanisms in a single tablet. This can simplify regimens compared with taking separate diuretic and ARB products, while providing comparable blood‑pressure reduction and fluid‑removal effects.

Store Izgrev tablets at temperatures below 25 °C, in the original container, and protect them from moisture and direct sunlight to maintain potency throughout the shelf life.

Izgrev is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a full glass of water.

Serious adverse events can include severe dehydration, marked electrolyte disturbances (especially low sodium or high potassium), acute kidney injury, and angioedema. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight loss, or persistent dizziness.

Izgrev is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, severe hepatic disease, or in those with a history of angioedema related to ARB therapy. It should also be avoided in individuals with markedly low blood pressure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT